Description: Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: US authorities accuse a former Lazard banker of tipping health-care mergers that generated about $41 million in illegal profits.

Description: Speaking at the J.P. Morgan Healthcare Conference 2026, CEO Daniel O’Day said that the company has seven pipeline drugs for HIV.

Description: In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading day.

Description: Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued blue chip stocks to buy now. On January 7, 2026, reports highlighted that analysts are increasingly confident in Gilead Sciences, Inc. (NASDAQ:GILD)’s short- and medium-term outlook, driven by optimism around the company’s HIV franchise. On that day, UBS analyst Michael Yee upgraded the stock from […]

Description: On January 6, 2026, OncoNano Medicine announced a research collaboration with Gilead Sciences to test its ON-BOARD encapsulation technology with a Gilead drug candidate, with OncoNano eligible for upfront, milestone and royalty payments and up to US$300.00 million if Gilead adds a second target. This collaboration underscores Gilead’s continued push to enhance drug delivery and efficacy in its pipeline, potentially reinforcing its focus on innovative therapies. Now we’ll examine how this...

Description: If you are wondering whether Gilead Sciences is fairly priced or offering value right now, this article will walk through what the numbers actually say about the stock. The share price recently closed at US$121.10, with returns of 0.6% over 30 days and 38.5% over 1 year. This may change how investors think about both upside and risk. Recent attention on Gilead has focused on its position in pharmaceuticals and biotech, as investors reassess major sector names in light of product pipelines,...

Description: BofA raised the firm’s price target on Gilead (GILD) to $154 from $144 and keeps a Buy rating on the shares. The firm, which switched its valuation method, says the company’s “steady” HIV franchise growth remains core to its Buy thesis as it sees upside from recent and upcoming launches.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's pote

Description: JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.

Description: The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.

Description: Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 08,

Description: Context for Gilead Sciences stock today Gilead Sciences (GILD) is in focus for investors after recent share price moves, with the stock showing mixed returns over the past week, month, and past 3 months, and a flat year to date performance. See our latest analysis for Gilead Sciences. At a share price of $121.36, Gilead Sciences has seen a 2.59% 1 day share price return alongside a 37.65% 1 year total shareholder return, which indicates recent momentum following a softer move year to date. If...

Description: The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in enhancing cancer immunotherapy, particularly for tumor types resistant to current treatments, through combination regimens and biomarker-driven strategies.Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook

Description: DALLAS, January 06, 2026--OncoNano Medicine, Inc. ("OncoNano") today announced a research collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) ("Gilead") to evaluate OncoNano’s ON-BOARD™ encapsulation technology with Gilead’s drug candidate.

Description: Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.

Description: Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior day's close.

Description: Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.

Description: KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.

Description: Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on Gilead to $151 from $147 with an Overweight rating on the shares. The firm informed investors that the regulatory and political uncertainties currently weighing on biopharma are expected to subside. […]

Description: In the latest trading session, Gilead Sciences (GILD) closed at $123.18, marking a -1.38% move from the previous day.

Description: Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 19, Gilead Sciences, Inc. (NASDAQ:GILD) announced an agreement with the US government aimed at lowering drug costs for Americans. The move reinforces the company’s long-standing focus on US-based innovation, affordability, and global health leadership. Under the […]

Description: Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.

Description: Health care stocks were rising in recent early Wednesday afternoon trading, with the NYSE Health Car

Description: (Updates with stock move in the headline and last paragraph.) Gilead Sciences (GILD) has signed a

Description: CAMBRIDGE, Mass. & MONTREAL, December 24, 2025--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the "Gilead Agreement").

Description: Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.

Description: FOSTER CITY, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:

Description: Gilead Sciences (GILD) said Monday that it has exercised its option to exclusively license Assembly

Description: FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio

Description: Investigator-initiated trial aims to provide proof-of-concept for bexmarilimab in overcoming acquired resistance to checkpoint inhibitors, a major challenge for most melanoma and lung cancer patients TURKU, FI / ACCESS Newswire / December 22, 2025 ...

Description: Bearish conditions on Wednesday turned bullish by Friday's close, with the S&P 500 and Nasdaq back above their 50-day lines. Palantir and GE lead a slew of new buys.

Description: Bearish conditions on Wednesday turned bullish by Friday's close, with the S&P 500 and Nasdaq back above their 50-day lines. Palantir and GE lead a slew of new buys.

Description: Bearish conditions on Wednesday turned bullish by Friday's close, with the S&P 500 and Nasdaq back above their 50-day lines. Palantir and GE lead a slew of new buys.

Description: Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.

Description: President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.

Description: Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t

Description: Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3.3% in the afternoon session after the stock's positive momentum continued as the company announced a series of positive developments, including successful late-stage trial results for a new HIV treatment, regulatory approval for another HIV drug in the U.K., and a new pricing agreement with the U.S. government.

Description: Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration. The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower. Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.

Description: FOSTER CITY, Calif., December 19, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based innovation, affordability, and global health leadership.

Description: All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige

Description: FOSTER CITY, Calif., December 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s senior leadership team and report to Chairman and Chief Executive Officer Daniel O’Day.

Description: Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy in the Phase 3 ARTISTRY 2 trial, with clean safety data that strengthens the longer term HIV pipeline story. See our latest analysis for Gilead Sciences. The stock has cooled a little in the last month, with a 30 day share price return of minus 4.6 percent. That still sits within a strong 32.1 percent year to date share price gain and a 5 year total shareholder return...

Description: Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news? Here is a breakdown of whether the current share price really lines up with the underlying value. Gilead is flat over the last week and down 2.2% over the past month, but the stock is still up 32.1% year to date and 37.6% over the last year, with gains of 58.2% in 3 years and 156.3% in 5 years. Behind these moves, investors have been reacting to a steady stream of...

Description: Gilead Sciences (GILD) closed the most recent trading day at $121.36, moving +2.17% from the previous trading session.

Description: Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

Description: The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new cell therapy player emerged and Sanofi cut deals with two startups.

Description: Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, December 19, 2025, the Index will be rebalanced, and the following changes will be effective.

Description: Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.

Description: FOSTER CITY, Calif., December 15, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically no

Description: Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent benefits as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma, including those previously considered ineligible for standard high-dose chemotherapy and stem cell transplant. This finding could encourage oncologists to use Yescarta earlier in the treatment pathway, potentially strengthening Gilead’s position in the fast-growing cell...

Description: Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.

Description: KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.

Description: A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target.

Description: The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.

Description: Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, the company delivered promising Pivotal Phase 2 study results of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. The company is developing an anti-CD in partnership with Kite, a Gilead company unit, […]

Description: ANNAPOLIS, Md. & PHILADELPHIA, December 10, 2025--Leading breast cancer nonprofits Unite for HER and TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA) presented new and critical research addressing health disparities, entitled "A New Comprehensive Integrative Care and Navigation Model for Enhancing Outcomes for Black Breast Cancer Patients: Evidence from the Care for HER Program​" at the 2025 San Antonio Breast Cancer Symposium.

Description: Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) on December 7, setting a price target of $135. The same day, Kite, a Gilead Sciences, Inc. (NASDAQ:GILD) company, released a new analysis showing that second-line Yescarta therapy […]

Description: Gilead Sciences, Inc. ( NASDAQ:GILD ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one...

Description: The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

Description: FOSTER CITY, Calif., December 09, 2025--Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast cancer.

Description: SANTA MONICA, Calif., December 07, 2025--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT).

Description: Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue growth expectations eased from around 3.89% to 3.68%. These modest adjustments reflect analysts fine tuning their models in light of a more nuanced mix of tailwinds, such as extended HIV cash flows and a larger PrEP opportunity, and headwinds, such as execution risk in next generation programs and...

Description: SANTA MONICA, Calif., December 06, 2025--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These ne

Description: SANTA MONICA, Calif., December 06, 2025--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #265) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

Description: Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: Gilead Sciences (GILD) just got a confidence boost from Wall Street, with Truist initiating coverage at Buy and Mizuho flagging a longer US exclusivity window for HIV flagship Biktarvy after key litigation settlements. See our latest analysis for Gilead Sciences. The mix of upbeat HIV and oncology commentary and a longer Biktarvy exclusivity window has helped support sentiment, with a roughly 36 percent year to date share price return and a 5 year total shareholder return above 150 percent...

Description: Vera Therapeutics recently appointed James R. Meyers, a biopharmaceutical executive with more than three decades of commercial leadership at companies including Gilead and AstraZeneca, to its Board of Directors. Meyers’ track record in leading global launches in HIV and HCV and guiding Gilead’s evolution into a large, profitable biopharma adds weight to Vera’s commercial ambitions as it advances its pipeline. We’ll now examine how adding Meyers’ extensive commercial expertise to the board...

Description: Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: SAN FRANCISCO, December 01, 2025--The National AIDS Memorial commemorated World AIDS Day with two powerful, community-centered events at the National AIDS Memorial Grove ("the Grove") in San Francisco. Having entered its 35th anniversary year in September 2025, the Grove has long served as a gathering place for remembrance and inspiration, reflecting the overarching theme of this year’s events: Community Driving Change. Gilead Sciences served as the Presenting Partner of both events.

Description: Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Boring Dividend Stocks to Buy. On Novemb‍er 24, Truist’​s‍ Gregor‌y Ren⁠za in​itiated coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with a Buy rating and se​t a price target of $14‌0, s‌lightly below th‌e pre​vi‌ous $1⁠45, as reported by The Fly. In‍ his note to investors,⁠ he […]

Description: Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased its price target for Gilead Sciences, Inc. (NASDAQ:GILD) from $131 to $140 while maintaining the stock’s Outperform rating. The firm cited a number of factors for the adjustment, including a longer exclusivity period for Biktarvy, with […]

Description: Earlier this month, Gilead Sciences announced the first shipments of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for HIV prevention to Eswatini and Zambia, marking a significant step in global access initiatives for this therapy. This move highlights Gilead’s ability to rapidly bring innovative HIV prevention to regions with high disease burden, fostering global health partnerships and expanding its reach in emerging markets. We'll now explore how Gilead's expanded...

Description: Ever wondered if Gilead Sciences might be trading for less than it's worth? Let’s dig into its recent moves to see if there's a value opportunity hiding in plain sight. Gilead Sciences' stock has been on the rise, climbing 6.2% over the past month and surging 37.0% year-to-date, for a strong 40.0% jump over the last year. Healthcare headlines have been buzzing, with recent positive developments around Gilead’s pipeline treatments and strategic partnerships attracting fresh attention from...

Description: GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.

Description: KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.

Description: Gilead’s new immunotherapy asset targets the TREX1 protein, which is a novel target in oncology.

Description: Gilead Sciences has outperformed the Dow Jones over the past year, and analysts are upbeat about the healthcare stock's prospects.

Description: The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”

Description: FOSTER CITY, Calif., November 24, 2025--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the Gilead Foundation, supports organizations addressing food insecurity in California, North Carolina,

Description: The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.

Description: Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.

Description: Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen's lead program, ANPD001, for moderate to advanced Parkinson's disease.

Description: Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining about 4%. With steady annual revenue and net income growth, there is renewed interest in how the company is positioned within the sector. See our latest analysis for Gilead Sciences. Gilead Sciences has enjoyed a wave of positive momentum lately, with its latest share price of $128.07 reflecting strong interest. The company’s share price return year-to-date stands at...

Description: FEATURE Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods. The appeal of this group is its variety.

Description: Liver failure is a critical condition where the liver loses its ability to detoxify, synthesize proteins, and regulate biochemical processes. It can result from hepatitis, alcohol abuse, NAFLD, autoimmune diseases, or toxins. Key symptoms include jaundice, encephalopathy, ascites, and bleeding. The global liver failure market is expanding due to rising disease prevalence, enhanced healthcare access, and diversified therapies. Innovations in transplantation, artificial liver systems, and pharmaco

Description: The global portal hypertension drugs market is thriving due to rising liver disease rates, particularly cirrhosis and hepatitis, and an aging global population, leading to heightened demand for effective therapies. Key players like Gilead Sciences and Novartis are driving market growth through innovation and strategic partnerships. Despite challenges such as high treatment costs and limited access, ongoing R&D aims to introduce affordable solutions. As awareness of liver health expands, technolo

Description: FOSTER CITY, Calif. & MBABANE, Eswatini, November 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people livi

Description: Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Passive Income Stocks to Buy Right Now. On November 12, Scotiabank an⁠aly​st Louise Chen began coverage on ten large-cap biopharma companies an⁠d sh​ared‍ an “‍o‌ut-of-c⁠onsensus” positive view o‌n the‍ sector, according to a report by The Fly. She pointed out that years of underperfor‍manc‌e in […]

Description: Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.

Description: Gilead Sciences recently announced that its Phase 3 ARTISTRY-1 trial met the primary endpoint for a novel single-tablet HIV regimen combining bictegravir and lenacapavir, confirming non-inferiority versus multi-tablet therapy and reporting a favorable safety profile. This development highlights Gilead’s continued progress in simplifying treatment for people living with HIV and advancing next-generation regimens that address patient needs for convenience and tolerability. We’ll examine how...

Description: Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

Description: Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: Pre-Market Stock Futures: The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction. The DJIA posted a record all-time high, closing at 48,254, up another 327 points or 0.68%. The S&P 500 just barely ... Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More

Description: FOSTER CITY, Calif., November 13, 2025--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non-inferior to multi-tablet regimens. Gilead plans to file t

Description: Curious whether Gilead Sciences is a hidden gem or if the current stock price already reflects all its upside? Let’s break down the numbers and see if there's value yet to be uncovered. After a strong year with a 37.2% gain and an impressive 34.3% jump year to date, the market’s perception of Gilead’s risk and growth potential appears to be evolving. Recent headlines highlight the company’s steady stream of new treatment approvals and strategic partnerships, both of which have bolstered...

Description: Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancerCash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on devel

Description: Compugen Ltd (CGEN) showcases promising drug discovery initiatives and strategic partnerships, despite facing revenue declines and trial delays.

Description: Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies due to rising PAH prevalence and greater awareness, alongside enhanced diagnostic capabilities. The shift towards personalized medicine and digital health tools also offers avenues for optimizing treatment efficacy and patient management. Pulmonary Arterial Hypertension Market Pulmonary Arterial Hypertension Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Pulmonary Art

Description: Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today reported financial results for the third quarter of 2025 and provided a corporate update.

Description: LOS ANGELES, November 10, 2025--As the pharmaceutical industry gathers for the Global Pharma & Biotech Summit in London this week, AIDS Healthcare Foundation (AHF) is launching a mobile billboard that will circle the venue (Convene 22 Bishopsgate) on Nov. 11-12 to spotlight Gilead Sciences’ greed and refusal to make its breakthrough HIV prevention drug lenacapavir truly affordable and accessible.

Description: Recent analyst updates have led to a slight increase in Gilead Sciences’ fair value price target, moving from $127.23 to $129.51. This change is supported by renewed confidence in the company’s performance and potential, along with a minor uptick in perceived investment risk. Stay tuned to see how you can keep up with evolving perspectives in this dynamic narrative. Stay updated as the Fair Value for Gilead Sciences shifts by adding it to your watchlist or portfolio. Alternatively, explore...

Description: Health care stocks edged lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1%

Description: Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the Health Care Se

Description: Gilead Sciences (GILD) said Friday that new long-term data on its drug Livdelzi showed consistent ef

Description: FOSTER CITY, Calif., November 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 criteria.

Description: FOSTER CITY, Calif., November 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Findings support Livdelzi's consistent efficacy and safety outcomes in patients switching from obeticholic acid and positive impact on liver stiffness over 3 years. These findings were presented at The Liver Meeting® hosted by the American Association for the

Description: Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (“Accipiter Bio”), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with

Description: Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader commercial headwinds. Management credited the quarter’s performance to robust demand for Biktarvy and Descovy, as well as the successful launch of Yeztugo for HIV prevention and Livdelzi for liver disease. CEO Daniel O’Day specifically highlighted the company’s “disciplined operating expense manage

Description: Gilead Sciences (GILD) released its third quarter earnings, showing a big jump in net income and earnings per share from last year. The company also raised its full-year profit outlook, which signals momentum. See our latest analysis for Gilead Sciences. Gilead Sciences has been on investors’ radar thanks to its raised earnings guidance and positive clinical updates, which have helped drive solid momentum. The stock boasts a year-to-date share price return of 33% and a stellar one-year total...

Description: Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: FOSTER CITY, Calif., November 04, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:

Description: Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.

Description: FOSTER CITY, Calif., November 03, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (December 6-9). These data showcase Kite’s continued progress in transforming blood cancer care and expanding the reach and impact of CAR T-cell therapy.

Description: Gilead Sciences (GILD) delivered a net profit margin of 27.9%, a sharp turnaround from just 0.4% a year ago, with earnings growth skyrocketing 6336.5% year over year. Looking ahead, management expects earnings to rise by 9.08% annually and revenue to grow at 4.5% per year, pointing to continued but more tempered expansion. Investors are weighing these strong headline results against prospects for steady future growth and value, especially with the company’s share price sitting below one major...

Description: In the opening hour of the evening session, U.S. equity futures are notably higher, with S&P 500 up 0.5% and Nasdaq 100 contracts up 1.0%. In commodities, WTI Crude Oil is little changed just above $60 per barrel while precious metals are stronger for the 3rd day in a row – Gold is above $4,040 and Silver is approaching $49 per ounce. A strong slate of quarterly Tech results are helping stock futures restore positive sentiment in the segment that was wounded on Thursday by more dubious results o

Description: Gilead stock reversed higher on smaller losses Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot.

Description: Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.

Description: FOSTER CITY, Calif., October 31, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceuti

Description: NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”). In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Pu

Description: Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.

Description: Gilead Sciences Inc (GILD) reports robust performance in HIV therapies, offsetting challenges in Veklury and cell therapy sales.

Description: Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention drug, Yeztugo.

Description: Gilead (GILD) delivered earnings and revenue surprises of +14.88% and +4.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Gilead Sciences reported third-quarter results that surpassed Wall Street expectations late Thursday, amid a close focus on the launch of the company’s promising new HIV medicine. Gilead shares are up 30% this year, largely on enthusiasm for Yeztugo, a twice-yearly HIV prevention shot that the FDA approved in June. Gilead said Thursday that sales of Yeztugo had been $39 million in the third quarter.

Description: Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q3 CY2025, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.

Description: GILD) on Thursday reported third-quarter earnings of $3.05 billion. On a per-share basis, the Foster City, California-based company said it had profit of $2.43. Earnings, adjusted for one-time gains and costs, came to $2.47 per share.

Description: FOSTER CITY, Calif., October 30, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations.

Description: New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on transformational busin

Description: In recent weeks, Gilead Sciences announced Health Canada's conditional approval of LYVDELZI (seladelpar) for primary biliary cholangitis, and presented new positive clinical data across its liver disease and oncology pipeline at major global conferences. This wave of regulatory and clinical milestones underscores Gilead's momentum in diversifying beyond its HIV franchise with late-stage therapies addressing major unmet needs. We'll examine how Health Canada’s approval for LYVDELZI and strong...

Description: WASHINGTON, October 29, 2025--Victory! AHF, 100 Organizations Kill Gilead’s Greedy Drug Price Hikes

Description: Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.

Description: Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close. Here’s what to expect.

Description: AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Description: The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Description: If you have been watching Gilead Sciences lately, you know it's been a whirlwind, and not in a way that will leave you dizzy, but rather with a sense of real momentum. Maybe you are holding the stock yourself and considering whether to double down, or perhaps you are just circling, wondering if now is finally the time to buy in. Let’s dig in together and see what might be going on beneath the surface. Over the last week, Gilead’s shares climbed 2.7%, which isn’t life-changing in itself, but...

Description: Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: FOSTER CITY, Calif., October 23, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C. Key findings from more than 35 accepted abstracts across PBC and viral hepatitis will include late-breaking data and three oral presentations.

Description: Gilead Sciences (GILD) concluded the recent trading session at $121.46, signifying a -2.11% move from its prior day's close.

Description: Gilead Sciences will release its third-quarter earnings later this month, and analysts anticipate a single-digit bottom-line growth.

Description: Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA alone, or as monotherapy in patients unable to tolerate UDCA. This market authorization has been issued with conditions pending the results of trials to verify its clinical benefit.

Description: WASHINGTON, October 21, 2025--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP

Description: FOSTER CITY, Calif., October 19, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in advancing antiviral science and its ongoing efforts to bring forward innovative solutions for people and communit

Description: FOSTER CITY, Calif., October 19, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. These findings will be presented to

Description: Gilead Sciences (GILD) is drawing attention this week as it presents new clinical results at both the European AIDS Conference and the European Society for Medical Oncology. Updates include HIV treatment advances and important data from cancer trials. See our latest analysis for Gilead Sciences. After unveiling positive data at major scientific conferences, Gilead Sciences is enjoying a notable run, with its share price climbing nearly 34% year-to-date and delivering an impressive 1-year...